Phase 1 study

Recruiting Phase 1

Sources: ClinicalTrials.gov Checked: 12 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 1
Sponsor Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Registry number NCT07676903
Started 13 August 2026 Today 16 October 2026 Estimated completion 1 October 2028

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Macquarie University Hospital North Ryde NSW Not yet recruiting
GenesisCare North Shore St Leonards NSW Not yet recruiting
Icon Cancer Centre South Brisbane South Brisbane QLD Not yet recruiting
Cancer Research SA Adelaide SA Not yet recruiting
Epworth HealthCare - Richmond Richmond VIC Not yet recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 12 October 2026 · not medical advice

Who can join

Age 18 Years to 75 Years
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 170

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

1. Have fully understood this study and voluntarily signed the informed consent form, with good compliance and cooperation with follow-up;

2. Age 18-75 years, any gender;

3. Performance status ECOG score 0 or 1;

4. Expected survival time greater than 3 months;

5. Presence of at least one measurable lesion according to RECIST 1.1 criteria;

6. Have adequate organ function;

7. Female participants of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose; and must not be lactating.

Exclusion Criteria:

1. Participants who have received any approved anti-tumor drugs (including investigational anti-tumor drugs) within 4 weeks prior to the first dose of the IP;

2. Toxicities from prior anti-tumor therapy have not recovered to ≤ Grade 1 or to the level specified in the inclusion/exclusion criteria;

3. Presence of central nervous system (CNS) metastases;

4. Concurrent active malignancy other than the primary tumor;

5. History of central nervous system diseases within 12 months prior to screening;

6. Participants who have undergone major surgery other than diagnostic or biopsy procedures within 28 days prior to the first dose, or who are expected to undergo major surgery during the study;

7. Participants with active tuberculosis or a history of active tuberculosis infection within ≤48 weeks prior to screening, regardless of treatment;

8. Presence of any significant clinical or laboratory abnormality that, in the investigator's opinion, affects safety evaluation;

9. History of deep vein thrombosis or pulmonary embolism within 6 months prior to screening;

10. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring clinical intervention;

11. Positive for human immunodeficiency virus (HIV) (HIV1/2 antibodies) with CD4+ T lymphocyte count \<350 cells/uL; or history of other acquired/congenital immunodeficiency diseases; or history of allogeneic bone marrow or solid organ transplantation;

12. Active chronic hepatitis B or active hepatitis C;

13. Known history of hypersensitivity to any component of the formulations used in the study;

14. Other factors, in the opinion of the investigator, that may affect the study results or result in forced halfway termination of this study, such as alcoholism, drug abuse, suffering from other serious diseases (including psychiatric disorders) requiring concomitant treatment, seriously abnormal laboratory test values, family or social factors and other conditions that may affect the safety of the patient or collection of study data.

Dates on the record

Started 13 August 2026
Estimated completion 1 October 2028
Registry last updated 5 October 2026
Checked by Voxsanity 12 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 5 October 2026.
  • This page last checked by Voxsanity: 12 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.